Greg is a partner at Menlo Ventures, where he invests in teams trying to solve major problems in life science and healthcare, with a special interest in novel therapeutic platforms, digital health, and transformative technologies. Since joining in 2017, Greg has led Menlo’s investments in Clear Labs, Delfi Diagnostics, Encoded Therapeutics, Epiodyne, Genesis Therapeutics, H1 Insights, Ophelia Health, Particle Health, Pliant Therapeutics (NASDAQ: PLRX), Senti Biosciences, Scribe Therapeutics and Riva Health. He has also been involved in investments in Benchling, Recursion Pharmaceuticals, and Cofactor Ge...read more